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Background: Little is known about the comparative effectiveness of atypical antipsychotics 
in long-acting injection formulation. Due to the absence of head-to-head studies comparing 
olanzapine long-acting injection and risperidone long-acting injection, this study was 
intended to make exploratory, indirect, cross-study comparisons between the long-acting 
formulations of these two atypical antipsychotics in their effectiveness in treating patients with 
schizophrenia.
Methods: Indirect, cross-study comparisons between olanzapine long-acting injection 
and risperidone long-acting injection used 12-month treatment-completion rates, because 
discontinuation of an antipsychotic for any cause is a recognized proxy measure of the 
medication’s effectiveness in treating schizophrenia. Following a systematic review of the 
literature, two indirect comparisons were conducted using open-label, single-cohort studies 
in which subjects were stabilized on an antipsychotic medication before depot initiation. The 
first analysis compared olanzapine long-acting injection (one study) with pooled data from 
nine identified risperidone long-acting injection studies. The second analysis was a “sensitivity 
analysis,” using only the most similar studies, one for olanzapine long-acting injection and one 
for risperidone long-acting injection, which shared near-identical study designs and involved 
study cohorts with near-identical patient characteristics. Pearson Chi-square tests assessed group 
differences on treatment-completion rates.
Results: Comparison of olanzapine long-acting injection data (931 patients) with the pooled 
data from the nine risperidone long-acting injection studies (3950 patients) provided almost 
identical 12-month treatment-completion rates (72.7% versus 72.4%; P = 0.87). When the two 
most similar studies were compared, the 12-month completion rate for olanzapine long-acting 
injection was significantly higher than for risperidone long-acting injection (81.3% versus 
47.0%; P , 0.001). However, any conclusions drawn from this comparison may be limited by 
differences in the studies’ geographic catchment areas.
Conclusion: Using treatment-completion rates as a proxy measure of medication effective-
ness, olanzapine long-acting injection did not differ significantly from risperidone long-acting 
injection when including all eligible studies. However, the findings of this exploratory analysis 
should be interpreted with caution, considering the methodological limitations of these indirect, 
cross-study comparisons.
Keywords: antipsychotic drugs, intramuscular injection, olanzapine, risperidone, 
schizophreniaInternational Journal of General Medicine 2012:5
Introduction
Nonadherence to medication is a major risk factor contributing 
to relapse and hospitalization among patients with schizophre-
nia.1,2 Treatment with antipsychotics in long-acting injection 
formulations (depot) is recognized as a safe and effective 
strategy for improving medication adherence3,4 and appears 
to benefit patients with schizophrenia who are nonadherent 
to medications.5 Currently, several atypical antipsychotics 
are available in long-acting “depot” injections: a microsphere 
formulation of risperidone6 (risperidone long-acting injec-
tion), a pamoate salt of olanzapine7 (olanzapine long-acting 
injection), and a palmitate ester of paliperidone,8 the major 
metabolite of risperidone. Still other long-acting injectable 
formulations are in development, such as a cholesterol-based, 
implantable preparation of aripiprazole.9 The earliest of these 
formulations to receive marketing approval in the United 
States, risperidone long-acting injection and olanzapine 
long-acting injection, have been available for several years. 
However, the comparative effectiveness of these two medica-
tions is unclear, as they have not been compared yet in any 
head-to-head study. The aim of this analysis was to compare 
the effectiveness of olanzapine long-acting injection and 
risperidone long-acting injection in the long-term, open-label 
treatment of patients with schizophrenia, using 12-month 
treatment-completion rates as a proxy measure of treatment 
effectiveness. Treatment-completion rate is considered a 
proxy measure of treatment effectiveness, as it reflects both 
patients’ and physicians’ judgments of the efficacy, safety, 
and tolerability of a medication.10,11 In previous head-to-head 
research of olanzapine and risperidone in standard oral tablet 
formulation in the treatment of schizophrenia, olanzapine-
treated patients were found to stay on therapy significantly 
longer and have significantly lower treatment-discontinuation 
rates compared with risperidone-treated patients.10–22 It is 
currently unknown whether findings from studies of the oral 
formulations of olanzapine and risperidone would extend to 
their depot formulations, as there are no head-to-head studies 
comparing the long-acting injectable formulations of these 
two medications.
Materials and methods
Data used in this analysis were identified via a systematic 
search of the published and unpublished literature. A search of 
the Embase® (Elsevier BV , Amsterdam, The Netherlands) and 
Medline® (National Library of Medicine, National Institutes 
of Health, Bethesda, MD) databases was conducted to iden-
tify relevant studies of olanzapine long-acting injection and 
risperidone long-acting injection using the following search 
terms: “olanzapine pamoate depot”, “olanzapine depot”, “olan-
zapine long-acting”, or “  long-acting olanzapine”, “Risperdal 
Consta”, “risperidone depot”, “risperidone   long-acting”, 
and “long-acting risperidone”. In addition, potentially rel-
evant olanzapine long-acting injection trials were identified 
via a search of the Eli Lilly internal database, and from the 
reference lists of identified studies and reviews.
Studies were eligible for inclusion in the analysis if they 
met the following criteria: an open-label design (ie, patients and 
investigators were aware of what treatment they were assigned 
to); patients received either olanzapine long-acting injection 
or risperidone long-acting injection (ie, only a “single cohort” 
was involved); age $ 18 years; inclusion of patients with a 
diagnosis of schizophrenia or a related disorder (for example, 
schizoaffective disorder); and availability of data reporting the 
proportion of patients completing at least 12 months of treat-
ment with olanzapine long-acting injection or risperidone long-
acting injection. In addition, studies had to include patients 
who were symptomatically stable at baseline. The latter 
criterion was included to increase comparability between the 
olanzapine long-acting injection and risperidone long-acting 
injection studies, because there has been only one olanzapine 
long-acting injection open-label, single-cohort study, F1D-
MC-HGKB (referred to hereafter simply as HGKB),23 and this 
study included patients who were stable at baseline.
Data regarding study and patient characteristics, as well as 
12-month completion rates, were extracted from the included 
studies. Two comparisons of 12-month completion rates were 
made. The first analysis compared data from the olanzapine 
long-acting injection study (HGKB) and all identified ris-
peridone long-acting injection studies that met the inclusion 
criteria. The second analysis was conducted as a form of sen-
sitivity analysis, comparing olanzapine long-acting injection 
data with that from the risperidone long-acting injection study 
that was most similar in design and patient characteristics. 
Group comparisons of 12-month treatment-completion rates 
were conducted using Fisher’s exact test.
Results
The literature search resulted in the identification of 
10 studies with 4901 patients (olanzapine long-acting injec-
tion, n = 931; risperidone long-acting injection, n = 3970; 
Table 1). Of the 10 studies, one was presented as an 
unpublished study report23 (F1D-MC-HGKB) providing 
effectiveness data on olanzapine long-acting injection and 
in two published articles,24,25 and nine publications provided 
effectiveness data on risperidone long-acting injection.26–34 
The HGKB olanzapine long-acting injection study23,25 was 
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an open-label, single-cohort extension study that enrolled 
patients from 128 sites in 25 countries in North and South 
America, Europe, Asia, Africa, the Middle East, and Australia 
who completed one of three previous clinical trials (“feeder 
studies”). The three trials included an 8-week randomized, 
double-blind, placebo-controlled inpatient study35 of olanzap-
ine long-acting injection (F1D-MC-HGJZ), a maintenance 
study36,37 in which patients stabilized on oral olanzapine 
for 4–8 weeks were randomly assigned to oral olanzapine 
or olanzapine long-acting injection for 24 weeks of double-
blind treatment (F1D-MC-HGKA), and a pharmacokinetic 
study38 of olanzapine long-acting injection (F1D-EW-LOBS). 
The 12-month treatment-completion rate on olanzapine 
long-acting injection was calculated twice, for two popula-
tions in the HGKB study: all HGKB patients, regardless of 
which feeder study they came from,23–25 and only patients 
who entered HGKB after completing HGKA, a randomized, 
controlled trial comparing olanzapine long-acting injection 
with oral olanzapine in patients with schizophrenia who were 
first stabilized on oral olanzapine (data on file, Eli Lilly and 
Company and/or one of its subsidiaries31,36).
The nine risperidone long-acting injection studies, with 
one exception, were single-cohort, open-label studies involv-
ing male or female adult (aged $ 18 years) patients. The one 
study that was an exception to the “single cohort” inclusion 
criterion34 had randomized patient treatment assignments to 
one of two dosing regimens of open-label risperidone long-
acting injection, and as such, was considered a single treatment 
cohort of risperidone long-acting injection. Of special interest 
was the study by Lindenmayer et al,31 which reported 12-month 
treatment-completion rates for two cohorts of patients being 
treated with open-label, flexible-dose risperidone long-acting 
injection in an extension study of two previous “feeder” 
studies: study A, which included patients from 41 sites in the 
United States who had either completed or been withdrawn 
from a 12-week, double-blind, randomized, controlled trial of 
inpatients comparing risperidone long-acting injection and 
placebo,39 and study B, which included patients from 28 sites 
in the United States who had completed a 12-week, open-
label outpatient study of risperidone long-acting injection.40 
Unlike study B, study A did not include all patients who had 
completed the feeder study, and it is unclear whether study A 
participants were stable when enrolled in the extension study 
by Lindenmayer et al.31 The 12-month treatment-completion 
rate for patients in study A was reported in the text39 to be 55%. 
However, other information reported for patient disposition 
(as represented in a figure of the published report of study A) 
indicated a 12-month completion rate of 50%.
Baseline characteristics of participants in each of the 
10 included studies are presented in Table 1. The majority 
of patients were male (62% to 69%) and had a diagnosis of 
schizophrenia (75% to 100%). Racial origin varied widely 
among the studies reporting racial origin, with Caucasians 
constituting as few as 40.2% of the patients in the Gharabawi 
et al study28 and as many as 92% of the patients in the study by 
Fleischhacker et al.27 Five studies did not report racial origin. 
Study participants also differed with regard to their baseline 
symptom severity, with mean baseline total scores on the 
Positive and Negative Syndrome Scale41 (PANSS) ranging 
from 54.5 (mildly ill42) in the HGKB study to 88.4 (mod-
erately to markedly ill42) in the study by Rossi et al,33 while 
baseline Clinical Global Impressions-Severity scale43 (CGI-S) 
scores ranged from 2.2 (borderline mentally ill to mildly ill) 
in study B of the Lindenmayer study31 to 4.6 (moderately to 
markedly ill) in the Olivares electronic Schizophrenia Treat-
ment Adherence Registry (e-STAR) study.32 Baseline PANSS 
scores were not provided for three of the 10 studies, and base-
line CGI-S scores were not provided for six of the studies.
In the HGKB study, 90% of all patients treated with 
olanzapine long-acting injection were outpatients at baseline, 
and 10% were inpatients.24 In the HGKA subgroup of the 
HGKB study,25 97% were outpatients at baseline, while 3% 
were inpatients (data on file). Information about outpatient 
and inpatient status at baseline was not reported in all risperi-
done long-acting injection studies. Studies reporting status 
indicated that the proportion of inpatients ranged from 0% 
in the studies by Rossi et al33 and Simpson et al34 to 34% in 
the Switch to Risperidone Microspheres (StoRMi) extension 
study by Kissling et al.29
As presented in Table 2, a comparison of data from all 
10 studies (analysis 1) showed nearly identical 12-month 
treatment-completion rates for patients treated with olanzap-
ine long-acting injection or risperidone long-acting injection 
(72.7% versus 72.4%, respectively; P = 0.87). Completion 
rates for risperidone long-acting injection ranged from 47.0% 
for study B conducted by Lindenmayer et al in the United 
States31 to 86.1% for the Olivares eSTAR study conducted 
in Spain.32
Due to the disparity between the included studies in 
their designs and patient baseline characteristics, a second 
analysis (analysis 2) was conducted between the two most 
similar studies as a form of sensitivity analysis. For olan-
zapine long-acting injection, this was the HGKA cohort 
from the HGKB study25 (n = 642; data on file), and for 
risperidone long-acting injection, it was the study B cohort 
(n = 100) from the study by Lindenmayer et al.31 There were 
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notable similarities between the two treatment groups that 
were compared in analysis 2:
•	 Both studies enrolled patients who had completed a previ-
ous “feeder” study of the corresponding depot medica-
tion and then continued into an extension period. These 
patients were likely similarly satisfied with their favorable 
response to treatment and thus willing to continue into 
the extension phase.
•	 Both studies included a single cohort of patients with 
schizophrenia.
•	 Both studies were open label, with flexible dosing of the 
medication.
•	 Both studies included chronically ill but stabilized 
patients with schizophrenia.
•	 Both studies included patients who were mildly ill, per mean 
PANSS total score or CGI scores.
•	 Both studies used identical prespecified inclusion criteria 
for baseline PANSS Positive scores (a score $ 4 on each 
of the following four PANSS positive items: conceptual 
disorganization, hallucinatory behaviors, suspiciousness, 
and unusual thought content).
•	 Both studies used a lead-in period of at least 4 weeks on 
the corresponding oral formulation prior to switching to 
the depot formulation.
•	 Participants in both studies had a similar mean age at 
study entry.
•	 Participants in both studies had a similar mean age at 
illness onset.
•	 Participants in both studies had a similar proportion of 
males and females.
Importantly, these patient characteristics (age at study entry, 
age at illness onset, and sex) have been previously found to 
be significant predictors of discontinuation on antipsychotic 
medications in the long-term treatment of patients with 
schizophrenia.44–50 However, the two comparison groups did 
differ in one important characteristic: geographic catchment 
area. Patients in the HGKA entry cohort of the olanzapine 
long-acting injection study represented 25 countries around 
the globe, whereas patients from the study B group of the 
risperidone long-acting injection trial were exclusively from 
the United States. The results of analysis 2 (Table 3) showed 
significantly higher 12-month treatment-completion rates for 
the HGKA cohort of the olanzapine long-acting injection trial 
compared with the study B group of the risperidone long-acting 
injection study (81.3% versus 47.0%, respectively; P , 0.001). 
It is noteworthy that, for study B, Lindenmayer et al31 reported 
two different treatment-completion rates, 52% in the text 
and 47% in a figure in the report; the correct rate is 47%, per 
personal communication from the principal author.
Discussion
This exploratory analysis made an indirect comparison 
between olanzapine long-acting injection and risperidone 
long-acting injection for 12-month treatment-completion rates 
using open-label, flexible-dose, single-cohort, prospective, 
observational studies conducted in the usual care of patients 
with schizophrenia. However, the findings from indirect cross-
study comparisons are susceptible to selection bias and other 
confounding variables. To help minimize potential bias, we 
conducted two separate analyses. The first analysis used all 
Table 2 Twelve-month completion rates for olanzapine long-
acting injectable or risperidone long-acting injectable (analysis 1)
Study Baseline  
medication(s)
OLAI 
n/N (%)
RLAI 
n/N (%)
hGKB23–25 OLAI 677/931  
(72.7)
chue et al26 Any antipsychotic 281/397 (70.7)
Fleischhacker et al27 Any antipsychotic 400/615 (65.0)
Gharabawi et al28 Oral risperidone 33/67b (49.3)
Kissling et al29  
(StorMi  
extension)
rLAI 508/715 (71.0)
Lee et al30 Oral antipsychotic 25/40 (62.5)
Lindenmayer et al31  
(study B)
rLAI 47/100 (47.0)
Olivares et al32  
(eSTAr Spain)
Any antipsychotic 1158/1345 (86.1)
rossi et al33 Any antipsychotic 243/347 (70.0)
Simpson et al34 Any antipsychotic 166/324 (51.2)
Overall 12-month  
completion ratea
677/931  
(72.7)
2861/3950 (72.4)
Notes: aP = 0.87, olanzapine-LAI versus pooled nine studies of risperidone-LAI, per 
Pearson chi-square test; bintent-to-treat population only.
Abbreviations: eSTAr, electronic Schizophrenia Treatment Adherence registry; n, 
number of patients completing 12 months of treatment; n, total number of patients 
treated; hGKB, study F1D-Mc-hGKB; OLAI, olanzapine long-acting injectable; rLAI, 
risperidone long-acting injectable; StorMi, Switch to risperidone Microspheres.
Table 3 Twelve-month completion rates for olanzapine long-
acting injectable or risperidone long-acting injectable (analysis 2)
Study Baseline 
medication(s)
OLAI 
n/N (%)
RLAI 
n/N (%)
hGKB24,25  
(hGKA subgroup, data on  
file, Eli Lilly and Company  
and/or one of its subsidiaries)
OLAI 522/642 
(81.3)
Lindenmayer et al31  
(study B)
rLAI 47/100 
(47.0)
Overall 12-month  
completion ratea
522/642 
(81.3)
47/100 
(47.0)
Notes: aP , 0.001, olanzapine-LAI versus risperidone-LAI, per Pearson chi-square test.
Abbreviations:  hGKA,  study  F1D-Mc-hGKA;  hGKB,  study  F1D-Mc-hGKB; 
n,  number  of  patients  completing  12  months  of  treatment;  n,  total  number  of 
patients  treated;  OLAI,  olanzapine  long-acting  injectable;  rLAI,  risperidone  long-
acting injectable.
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eligible studies reporting 12-month treatment-completion rates 
and found no significant difference between the two depot drugs 
on treatment-completion rates. However, because medication 
discontinuation rates tend to be influenced by study design, 
country of study sites, study burden, and patients’ clinical and 
demographic characteristics, we also attempted to conduct 
an additional sensitivity analysis by selecting the risperidone 
long-acting injection study most similar to the single olanzapine 
long-acting injection study that was available. This was 
done due to the marked heterogeneity among the nine available 
risperidone long-acting injection studies and the need to 
compare “like with like.” The second analysis, which compared 
results from two studies that were most similar in both their 
methodology and patient characteristics, found a significantly 
higher treatment-completion rate for olanzapine long-acting 
injection compared with risperidone long-acting injection. 
Results from the second analysis are consistent with those 
from head-to-head comparative studies of oral olanzapine 
and risperidone,10–22 as well as the results of two other recent 
and similarly designed studies in the treatment of patients in 
the United States with schizophrenia.51,52 One study52 was a 
randomized, open-label, 2-year study that compared risperidone 
long-acting injection and oral atypical antipsychotics and 
reported a high rate of discontinuation (approximately 80%) of 
risperidone long-acting injection for any cause over the 2-year 
study. The other study51 was also a randomized, open-label, 
2-year study comparing olanzapine long-acting injection and 
oral olanzapine, and that study found a relatively lower 2-year 
discontinuation rate (54.9%) for any cause on olanzapine long-
acting injection. However, it is notable that the “most similar” 
risperidone long-acting injection study used in our second 
analysis reported a considerably lower treatment-completion 
rate compared with the other eight risperidone long-acting 
injection studies.27,29,30,32,33,53–55 Moreover, the two studies in 
analysis 2 differed with respect to their catchment areas, in that 
the risperidone long-acting injection study B was conducted 
exclusively in the United States, while the olanzapine long-
acting injection study was conducted more globally, outside 
the United States. This may account in large part for the 
observed disparity in discontinuation rates, because regional 
differences may lead to differences in study discontinuation 
rates.56 A recent paper about a 2-year, single-cohort, open-
label study56 of risperidone long-acting injection found the 
2-year treatment-completion rates for risperidone long-acting 
injection to differ markedly among the four countries studied, 
ranging from 39.3% in the United States to 62.7% in Spain. 
The authors noted that, “variation in discontinuation among the 
four countries may be due to differences in access to treatment, 
social support (for example, in patients who live alone), and 
cost (for example in Spain, RLAT [risperidone long-acting 
injection] is free to most patients).” This information strongly 
suggests that the present exploratory comparison would require 
more definitive proof in the form of a direct, head-to-head 
comparison under essentially identical study conditions and 
in the same geography/country to clarify the validity of the 
current findings.
The current analyses are the first to compare the effec-
tiveness of olanzapine long-acting injection and risperidone 
long-acting injection side by side and are preliminary and 
exploratory in nature. Therefore, there is a need to interpret 
the findings cautiously in the context of their limitations. As 
noted previously, these analyses were carried out using data 
from open-label, single-cohort studies, which are susceptible 
to selection bias and other confounding variables, including the 
country or countries where the study was conducted. Moreover, 
there is an imbalance in study representation, with just a single 
olanzapine long-acting injection study being compared with 
multiple risperidone long-acting injection studies, the latter 
being associated with a greater pooled variation in the total 
patient sample. While every effort was made in our study to 
ensure comparability of the data used by comparing the two 
studies most similar in study design and patient baseline 
characteristics, the differences between olanzapine long-acting 
injection and risperidone long-acting injection in the 12-month 
treatment-completion rates could have been an artifact due 
to differences in the studies’ geographies, which often reflect 
differences in health care practices, social supports, and 
medication costs. Therefore, the current findings should be 
interpreted cautiously with these limitations in mind. There is a 
clear need for comparative head-to-head studies of olanzapine 
long-acting injection and risperidone long-acting injection in 
the long-term treatment of patients with schizophrenia, to help 
accurately delineate the comparative effectiveness of these two 
atypical antipsychotics in depot formulations.
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